

**Supporting Information for**

**Structural basis for catalysis and ubiquitin recognition by the severe acute  
respiratory syndrome coronavirus papain-like protease**

Chi-Yuan Chou<sup>1,\*</sup>, Hsing-Yi Lai<sup>1,#</sup>, Hung-Yi Chen<sup>1,#</sup>, Shu-Chun Cheng<sup>1,#</sup>, Kai-Wen  
Cheng<sup>1</sup>, and Ya-Wen Chou<sup>1</sup>

<sup>1</sup>Department of Life Sciences and Institute of Genome Sciences, National Yang-Ming  
University, Taipei 112, Taiwan

---


<sup>#</sup>Equal contributions

<sup>\*</sup>Correspondence information for Chi-Yuan Chou


Phone: +886-2-28267168; FAX: +886-2-28202449

E-mail: [cychou@ym.edu.tw](mailto:cychou@ym.edu.tw)


5 supplement figures included.




**Supplement Fig. 1. Protein content analysis of PL<sup>pro</sup> C112S-Ub co-crystals by SDS-PAGE.** Lane 1 and 2 show the results of two crystals with size of 0.2 and 0.8 mm, respectively.




**Supplement Fig. 2. Continuous  $c(s)$  distributions of SARS-CoV PL<sup>pro</sup> without (A) and with Ub (B) by AUC analysis.** The protein concentration of wild-type PL<sup>pro</sup> in panel A was 0.2 mg/ml. In panel B, wild-type PL<sup>pro</sup> (0.2 mg/ml) and Ub (1 mg/ml) were overnight incubated at 4 °C and then analyzed by AUC. The detailed AUC and analyzing methods are described in experimental procedures.




**Supplement Fig. 3. Deubiquitinating activity assay of SARS-CoV PL<sup>pro</sup> and its mutants.** Fluorescence versus time progress curves for hydrolysis of Ub-AFC (0.5  $\mu$ M) at 30 °C. The results of wild-type, L163Q, D165A, E168A, E168D, E168R, Y265A, and Y265F mutants are colored by blue, purple, cyan, red, magenta, green, yellow, and brown, respectively. The protein concentration of wild-type, L163Q, E168D, and Y265F mutant used for the assay was 0.17  $\mu$ M, while that of D165A, E168A, E168R, and Y265A was 0.51  $\mu$ M. The excitation and emission wavelength was 350 and 485 nm, respectively.



**Supplement Fig. 4. Continuous  $c(s)$  distributions of SARS-CoV PL<sup>pro</sup> C112S/E168R double mutant without (A) and with Ub (B) by AUC analysis.** The protein concentration of PL<sup>pro</sup> C112S/E168R double mutant in panel A was 0.2 mg/ml. In panel B, PL<sup>pro</sup> C112S/E168R double mutant (0.2 mg/ml) and Ub (1 mg/ml) were overnight incubated at 4 °C and then analyzed by AUC. The detailed AUC and analyzing methods are described in experimental procedures.



**Supplement Fig. 5. Comparison with the active site of free wild-type SARS-CoV PL<sup>pro</sup>.** Overlay of the active site region of the PL<sup>pro</sup> C112S mutant (color) in complex with Ub (yellow) and that of free PL<sup>pro</sup> (grey). The arrow indicates the movement of the residue Tyr269 on the BL2 loop.



**Supplement Fig. 6. Comparison of the ubiquitin-binding surfaces of SARS-CoV PL<sup>P</sup>, USP2, and USP14.** The ubiquitin molecule is shown as a ribbon diagram (in yellow) and the molecular surface of PL<sup>P</sup> (A), human USP2 (B, PDB code: 2HD5), and USP14 (C, PDB code: 2AYO) are colored by potential (red for negative and blue for positive charge). The tip of the fingers domain is indicated by oval circles and location of the binding loop 1 (BL1) of USP2 and USP14 is labeled, respectively.